DCPH Nasdaq

Deciphera Pharmaceuticals, Inc.

DCPH | $14.235 -3.3% -3.41% 760K

(0.0% 1d) (-5.8% 1m) (1.2% 1y) (0.0% 2d) (0.0% 3d) (-0.4% 7d) (-48.47% volume)
Earnings Calendar: 2024-02-07
Market Cap: $ 1,150,188,883
http://www.deciphera.com
Sec Filling | Patents | 258 employees

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

cancer gastrointestinal tumor cells t-cell msa treatment ceiling

add to watch list Paper trade email alert is off

Press-releases

Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| -2.78% | O: -2.13% H: 5.02% C: 4.69%
pharmaceuticals

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| -9.73% | O: 0.67% H: 2.36% C: 2.18%
pharmaceuticals

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
Published: 2024-02-01 (Crawled : 00:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| 3.63% | O: 0.07% H: 3.42% C: 3.0%
conference year pharmaceuticals financial results

Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 13:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| 3.63% | O: 0.07% H: 3.42% C: 3.0%
conference pharmaceuticals

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Published: 2024-01-18 (Crawled : 21:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| 4.95% | O: 0.0% H: 1.77% C: -1.77%
symposium pharmaceuticals gastrointestinal results study

Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| -8.0% | O: -0.93% H: 6.82% C: 3.57%
conference pharmaceuticals

Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Published: 2023-11-29 (Crawled : 15:30) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| 21.74% | O: 0.74% H: 4.32% C: 0.98%
pharmaceuticals

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - November 7, 2023
Published: 2023-11-07 (Crawled : 16:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology

| 23.05% | O: 0.5% H: 1.73% C: -1.82%
pharmaceuticals

Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
Published: 2023-10-30 (Crawled : 00:00) - biospace.com/
DCPH | $14.235 -3.3% -3.41% 760K

Health Technology